Monoclonal antibodies still a booming market despite advent of biologics

Next-generation monoclonal antibody-based platforms will find particularly promising application in precision medicine, according to market research firm Frost & Sullivan.

Monoclonal antibodies have received a great deal of attention over the past two decades, with more than 500 companies operating in this space. The global monoclonal antibody therapeutics market is expected to expand at a compound annual growth rate of 8.1% between 2014 and 2020.

Cecilia Van Cauwenberghe, an analyst at Frost & Sullivan’s TechVision practice, said: “Efforts to create advanced molecular agents indicate the top biopharmaceutical companies’ strong focus on biologics. However, during cell line generation, which is an important part of the molecular agent development process, it will be challenging to ensure the optimization of the cell expression system to increase capacity.”